IMMUNEERING CORP CLASS A (IMRX)
Health Care · Clinical-stage oncology / targeted cancer therapeutics · NASDAQ
Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors, a novel class of MEK/MAPK inhibitors designed to improve durability and tolerability in cancer by reducing toxicity and resistance through cadenced signaling inhibition.
What IMMUNEERING CORP CLASS A does
Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors (DCI), a novel class of anti-cancer medicines designed to disrupt tumor cell proliferation while sparing healthy cells through cadenced signaling. The company's lead candidate, atebimetinib (IMM-1-104), is an oral MEK inhibitor in Phase 3 development for first-line pancreatic cancer in combination with modified gemcitabine/nab-paclitaxel, with a secondary program (envometinib) and preclinical research focused on MAPK and other core cancer signaling pathways.
Themes: ["MEK inhibitors / MAPK pathway","Targeted oncology","Pancreatic cancer","Non-small cell lung cancer","Precision medicine / translational bioinformatics","Resistance-overcoming therapeutics"]
Fundamentals
- Price$5.36 as of 2026-07-09 close
- Market cap$347M as of 2026-07-10
- 1-year return+38.3% as of 2026-07-09 close
- Net margin-9610.0% as of 2026-07-10
- Gross margin+28.0% as of 2026-07-10
- ROE-31.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.24 as of 2026-07-10
Key risks (from latest filing)
["Atebimetinib is in early Phase 3 development with no approved products; failure of the MAPKeeper 301 trial would jeopardize the lead program and company viability.","The company is unprofitable with a net margin of -9610% and has financed operations through debt and equity offerings; continued clinical development requires sustained funding.","DCI represents a novel mechanism of action; clinical and commercial validation is unproven, and competitive MEK/MAPK inhibitors from larger pharma may limit market adoption."]
Competitors & peers
- Array BioPharma (now part of Pfizer) — MEK inhibitors
- Roche / Carmot — MAPK pathway inhibitors
- Amgen — oncology targeted therapies
- Incyte — precision oncology
- BeiGene — targeted cancer medicines
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.